Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $198.9 million.

  • Amicus Therapeutics' Total Current Liabilities rose 25.80% to $198.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 25.80%. This contributed to the annual value of $148.7 million for FY2024, which is 11.32% down from last year.
  • As of Q3 2025, Amicus Therapeutics' Total Current Liabilities stood at $198.9 million, which was up 18.66% from $167.6 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Total Current Liabilities ranged from a high of $198.9 million in Q3 2025 and a low of $99.7 million during Q1 2021.
  • Its 3-year average for Total Current Liabilities is $161.0 million, with a median of $159.2 million in 2023.
  • In the last 5 years, Amicus Therapeutics' Total Current Liabilities surged by 47.00% in 2022 and then declined by 11.32% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Total Current Liabilities (Quarterly) stood at $146.0 million in 2021, then declined by 4.77% to $139.0 million in 2022, then rose by 20.62% to $167.7 million in 2023, then fell by 11.32% to $148.7 million in 2024, then rose by 25.80% to $198.9 million in 2025.
  • Its Total Current Liabilities was $198.9 million in Q3 2025, compared to $167.6 million in Q2 2025 and $152.9 million in Q1 2025.